6Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation,2000, 102(20 Suppl 4) : Ⅳ14-Ⅳ23.
7Hunt SA, Abraham WT, Chin MA, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: a report of the ACC foundation/AHA task force on practice guidelines. J Am Coll Cardiol, 2009,53 : 1343-1382.
8Yusuf S, Preffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet,2003,362: 777-781.
9Massie BM, Carson PE, McMurray JJ, et al. (I-PRESERVE Investegators ). Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med, 2008,359: 2456- 2467.
10Owan TE, Hodge DO, Herges RM, et al. Trends in prevalance and outcome of heart failure with preserved ejection fraction. N Engl J Med, 2006,355 : 251-259.
4Hayashida W, Doncekier J, Van Mechelen H, et al. Load sensitive diastole relax action in hypertyophied left ventricular [ J ]. Am J Physiol,1998,274(2Pt 2) :609.
5Simone G,Greco R,Mureddu G,et al. Relation of left ventricular diastolic popperties to systolic function in arteria hypertension [ J ]. Circulation ,2000,101 ( 2 ) : 152.
6Dahlof B, Devereux R B, Kjeldsen S E, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study ( LIFE ) : a randomized trial againstatenolol [ J ]. lancet,2002,359 ( 9311 ) : 995 -1003.
7Diez J, Quereeta R,Lopcz B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left vcntricular chamber stiffness in hypertension patients [ J ]. Circulation, 2002,105 ( 2 ) : 2512-2517.
8Angeja BG, Grossman W. Evaluation and management of diastolic heart failure [ J]. Circulation ,2003,107 (5) :659-663.
9Aurigemma G R, Gaasch W H. Diastolic heart fatlure[ J ]. N Engl JMe d ,2004,35 1 ( 11 ) : 1097-1105.
10Yusuf S, Pfeffer MA, Swedberg K,et al. Effects of candesart an in patients with chronic heart failure and preserved eftventricular ejection fraction : the CHARM-Preserved Trial [ J ]. Lancet, 2003, 362(938 6) :777-781.
